Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a $17 price target.
May 28, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Reviva Pharmaceuticals and maintained a $17 price target.
The reiteration of a Speculative Buy rating and the maintenance of a $17 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100